Patents Assigned to Taisho Pharmaceutical Co., Ltd.
  • Publication number: 20210147400
    Abstract: Provided is a novel process for producing a (2S)-2-[(1H-pyrazol-1-yl)methyl]-1,3-oxazinane derivative. More specifically, provided is a process for producing a (2S)-2-[(1H-pyrazol-1-yl)methyl]-1,3-oxazinane derivative represented by formula (1): the process comprising reacting 3-aminopropan-1-ol with glyoxylic acid.
    Type: Application
    Filed: July 11, 2018
    Publication date: May 20, 2021
    Applicant: TAISHO PHARMACEUTICAL CO., LTD.
    Inventors: Takaaki MATSUBARA, Hiroki URABE, Ryo SUZUKI, Aya FUTAMURA, Ryo KINOSHITA, Nobutaka HATTORI, Hideaki TABUSE, Koreaki IMURA, Norikazu OTAKE
  • Publication number: 20210122741
    Abstract: The present invention provides a compound represented by formula [I] shown below or a pharmaceutically acceptable salt thereof that has an inhibitory effect on 20-HETE producing enzyme.
    Type: Application
    Filed: August 10, 2018
    Publication date: April 29, 2021
    Applicant: TAISHO PHARMACEUTICAL CO., LTD
    Inventors: Hiroaki TANAKA, Madoka KAWAMURA, Makoto HAMADA, Yohei KOBASHI, Yuji ITO, Kazuaki SUZUKI, Ayako BOHNO, Kosuke FUNAYAMA
  • Publication number: 20210070747
    Abstract: Provided are: useful novel compounds that exhibit antibacterial activity based on their actions for inhibiting GyrB of DNA gyrase and ParE of topoisomerase IV; and 2(1H)-quinolinone derivatives represented by formula [1]: or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: March 23, 2018
    Publication date: March 11, 2021
    Applicant: TAISHO PHARMACEUTICAL CO., LTD.
    Inventors: Hideaki AMADA, Norikazu OTAKE, Fumihito USHIYAMA, Chunhae KIM, Tomoki TAKEUCHI, Nozomi TANAKA
  • Publication number: 20210040062
    Abstract: The present invention provides a compound represented by formula [I?] shown below or a pharmaceutically acceptable salt thereof that has an inhibitory effect on 20-HETE producing enzyme, wherein the structure represented by formula [III] shown below represents any of the structures represented by formula group [IV] shown below, wherein R1 represents a hydrogen atom, a fluorine atom, methyl, etc.; R2, R3, and R4 each independently represent a hydrogen atom, a fluorine atom, or methyl; W represents a single bond, C1-3alkanediyl, or the formula —O—CH2CH2—; and ring A represents (a) substituted C4-6cycloalkyl, (b) substituted 4- to 6-membered saturated nitrogen-containing heterocyclyl, (c) substituted phenyl, (d) substituted pyridyl, (e) substituted 2,3-dihydrobenzofuran, (f) 4- to 6-membered saturated oxygen-containing heterocyclyl, etc.
    Type: Application
    Filed: February 14, 2017
    Publication date: February 11, 2021
    Applicant: TAISHO PHARMACEUTICAL CO., LTD.
    Inventors: Hiroaki TANAKA, Ayako BOHNO
  • Patent number: 10689327
    Abstract: Provided is an amino acid derivative prodrug represented by general formula (I-A) that is a prodrug form of an amino acid derivative which is a group 2 metabotropic glutamate receptor antagonist, or a pharmaceutically acceptable salt thereof. More specifically, provided is an amino acid derivative prodrug represented by general formula (I-A) that is a preventive or therapeutic drug for mood disorders (including depression and bipolar disorder), anxiety disorder, cognitive disorders, developmental disorders, Alzheimer's disease, Parkinson's disease, movement disorders associated with muscular rigidity, sleep disorders, Huntington's chorea, eating disorders, drug dependence, epilepsy, brain infarction, cerebral ischemia, cerebral insufficiency, cerebral edema, spinal cord disorders, head trauma, inflammation and immune-related diseases, and so on.
    Type: Grant
    Filed: July 15, 2019
    Date of Patent: June 23, 2020
    Assignee: TAISHO PHARMACEUTICAL CO., LTD.
    Inventors: Norikazu Otake, Takashi Hashihayata, Yohei Matsuda, Seiji Masuda, Yuko Yamauchi
  • Publication number: 20190337887
    Abstract: Provided is an amino acid derivative prodrug represented by general formula (I-A) that is a prodrug form of an amino acid derivative which is a group 2 metabotropic glutamate receptor antagonist, or a pharmaceutically acceptable salt thereof. More specifically, provided is an amino acid derivative prodrug represented by general formula (I-A) that is a preventive or therapeutic drug for mood disorders (including depression and bipolar disorder), anxiety disorder, cognitive disorders, developmental disorders, Alzheimer's disease, Parkinson's disease, movement disorders associated with muscular rigidity, sleep disorders, Huntington's chorea, eating disorders, drug dependence, epilepsy, brain infarction, cerebral ischemia, cerebral insufficiency, cerebral edema, spinal cord disorders, head trauma, inflammation and immune-related diseases, and so on.
    Type: Application
    Filed: July 15, 2019
    Publication date: November 7, 2019
    Applicant: TAISHO PHARMACEUTICAL CO., LTD.
    Inventors: Norikazu OTAKE, Takashi HASHIHAYATA, Yohei MATSUDA, Seiji MASUDA, Yuko YAMAUCHI
  • Patent number: 10464884
    Abstract: Provided is an amino acid derivative prodrug represented by general formula (I-A) that is a prodrug form of an amino acid derivative which is a group 2 metabotropic glutamate receptor antagonist, or a pharmaceutically acceptable salt thereof. More specifically, provided is an amino acid derivative prodrug represented by general formula (I-A) that is a preventive or therapeutic drug for mood disorders (including depression and bipolar disorder), anxiety disorder, cognitive disorders, developmental disorders, Alzheimer's disease, Parkinson's disease, movement disorders associated with muscular rigidity, sleep disorders, Huntington's chorea, eating disorders, drug dependence, epilepsy, brain infarction, cerebral ischemia, cerebral insufficiency, cerebral edema, spinal cord disorders, head trauma, inflammation and immune-related diseases, and so on.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: November 5, 2019
    Assignee: TAISHO PHARMACEUTICAL CO., LTD.
    Inventors: Norikazu Otake, Takashi Hashihayata, Yohei Matsuda, Seiji Masuda, Yuko Yamauchi
  • Patent number: 10207976
    Abstract: A novel process for producing optically active 2-(2-fluorobiphenyl-4-yl)propanoic acid is disclosed. This production process is characterized in that a compound of formula [1] is reacted with magnesium and so forth to prepare an organometallic reagent, which is reacted with a compound of formula [2] in the presence of a catalytic amount of a nickel compound and a catalytic amount of an optically active compound of formula [3] to obtain a compound represented by formula [4] which is subsequently converted to a compound represented by formula [5] or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: February 19, 2019
    Assignee: TAISHO PHARMACEUTICAL CO., LTD
    Inventors: Norikazu Otake, Daisuke Matsuda, Rie Shimono, Hideaki Tabuse, Minoru Moriya, Yohei Kobashi, Yohei Matsuda, Tomokazu Tamaoki
  • Publication number: 20190047943
    Abstract: Provided is an amino acid derivative prodrug represented by general formula (I-A) that is a prodrug form of an amino acid derivative which is a group 2 metabotropic glutamate receptor antagonist, or a pharmaceutically acceptable salt thereof. More specifically, provided is an amino acid derivative prodrug represented by general formula (I-A) that is a preventive or therapeutic drug for mood disorders (including depression and bipolar disorder), anxiety disorder, cognitive disorders, developmental disorders, Alzheimer's disease, Parkinson's disease, movement disorders associated with muscular rigidity, sleep disorders, Huntington's chorea, eating disorders, drug dependence, epilepsy, brain infarction, cerebral ischemia, cerebral insufficiency, cerebral edema, spinal cord disorders, head trauma, inflammation and immune-related diseases, and so on.
    Type: Application
    Filed: April 18, 2017
    Publication date: February 14, 2019
    Applicant: TAISHO PHARMACEUTICAL CO., LTD.
    Inventors: Norikazu OTAKE, Takashi HASHIHAYATA, Yohei MATSUDA, Seiji MASUDA, Yuko YAMAUCHI
  • Publication number: 20180282252
    Abstract: A novel process for producing optically active 2-(2-fluorobiphenyl-4-yl)propanoic acid is disclosed. This production process is characterized in that a compound of formula [1] is reacted with magnesium and so forth to prepare an organometallic reagent, which is reacted with a compound of formula [2] in the presence of a catalytic amount of a nickel compound and a catalytic amount of an optically active compound of formula [3] to obtain a compound represented by formula [4] which is subsequently converted to a compound represented by formula [5] or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 29, 2016
    Publication date: October 4, 2018
    Applicant: TAISHO PHARMACEUTICAL CO., LTD.
    Inventors: Norikazu OTAKE, Daisuke MATSUDA, Rie SHIMONO, Hideaki TABUSE, Minoru MORIYA, Yohei KOBASHI, Yohei MATSUDA, Tomokazu TAMAOKI
  • Patent number: 10022389
    Abstract: New drugs useful in the prevention or treatment of constipation are provided, in which SGLT1 inhibiting compounds, in particular, a 4-isopropylphenyl glucitol compound represented by the following formula (I), or pharmaceutically acceptable salts thereof are contained as an active ingredient:
    Type: Grant
    Filed: February 3, 2014
    Date of Patent: July 17, 2018
    Assignee: TAISHO PHARMACEUTICAL CO., LTD.
    Inventors: Daisuke Yamamoto, Fusayo Io, Koji Yamamoto
  • Patent number: 9932331
    Abstract: The present invention provides a compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof which has an excellent NHE3 inhibitory effect: A-Y??[1] wherein A represents a structure represented by the following formula [2]: wherein R11 and R12 each represent a halogen atom or others as described herein, R2 represents C1-6 alkyl or others as described herein, ring E represents triazole, tetrazole, pyrimidine, or others as described herein, R31 and R32 each represent a hydrogen atom, C1-6 alkyl, C1-6 alkoxy, or others as described herein, and W represents a single bond, the formula —NH—, the formula —O—, or the formula —CONH—, and Y represents a hydrogen atom or a structure selected from
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: April 3, 2018
    Assignee: TAISHO PHARMACEUTICAL CO., LTD.
    Inventors: Shoichi Kuroda, Kenichi Kawabe, Yasunobu Ushiki, Hiroshi Ohta, Fumito Uneuchi, Tsuyoshi Shibata, Hideaki Tabuse, Eiji Munetomo, Sumi Chonan
  • Publication number: 20170267708
    Abstract: A useful novel compound that shows superior antibacterial activity also against erythromycin resistant bacteria, for example, resistant pneumococci, streptococci, mycoplasmas, and the like, against which sufficient antibacterial activity cannot be obtained with conventional macrolide antibiotics, or a pharmaceutically acceptable salt thereof, or a hydrate or a solvate thereof.
    Type: Application
    Filed: August 17, 2015
    Publication date: September 21, 2017
    Applicant: TAISHO PHARMACEUTICAL CO., LTD.
    Inventors: Tomohiro SUGIMOTO, Masato HAYASHI, Takanori KAWAGUCHI
  • Publication number: 20170210736
    Abstract: The present invention provides a compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof which has an excellent NHE3 inhibitory effect: [Formula 15] A-Y??[1] wherein A represents a structure represented by the following formula [2]: wherein R11 and R12 each represent a halogen atom or the like, R2 represents C1-6 alkyl or the like, ring E represents triazole, tetrazole, pyrimidine, or the like, R31 and R32 each represent a hydrogen atom, C1-6 alkyl, C1-6 alkoxy, or the like, and W represents a single bond, the formula —NH—, the formula —O—, or the formula —CONH—, and Y represents a hydrogen atom or a structure represented by the following formula [3?]:
    Type: Application
    Filed: July 24, 2015
    Publication date: July 27, 2017
    Applicant: TAISHO PHARMACEUTICAL CO., LTD
    Inventors: Shoichi KURODA, Kenichi KAWABE, Yasunobu USHIKI, Hiroshi OHTA, Fumito UNEUCHI, Tsuyoshi SHIBATA, Hideaki TABUSE, Eiji MUNETOMO, Sumi CHONAN
  • Patent number: 9522914
    Abstract: The present invention provides agents for treating or preventing diseases such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, alopecia, and so forth.
    Type: Grant
    Filed: October 25, 2012
    Date of Patent: December 20, 2016
    Assignee: TAISHO PHARMACEUTICAL CO., LTD
    Inventors: Mitsukane Yoshinaga, Takeshi Kuwada, Naoki Miyakoshi, Tomoko Ishizaka, Daisuke Wakasugi, Shin-ichi Shirokawa, Nobutaka Hattori, Youichi Shimazaki
  • Patent number: 9499477
    Abstract: Provided is a novel compound which is useful as a pharmaceutical composition by inhibiting an LpxC activity, thereby exhibiting potent antimicrobial activity against gram-negative bacteria including Pseudomonas aeruginosa and its drug resistant bacteria. Provided is a hydroxamic acid derivative represented by the following general formula [1] or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: November 22, 2016
    Assignees: TOYAMA CHEMICAL CO., LTD., TAISHO PHARMACEUTICAL CO., LTD
    Inventors: Hajime Takashima, Risa Tsuruta, Tetsuya Yabuuchi, Yusuke Oka, Hiroki Urabe, Yoichiro Suga, Masato Takahashi, Fumito Uneuchi, Hironori Kotsubo, Muneo Shoji, Yasuko Kawaguchi
  • Publication number: 20160289208
    Abstract: This 2-pyridone compound represented by formula [1] or a tautomer of said compound, or a pharmaceutically acceptable salt of said compound or said tautomer, or a solvate of said compound or the like has a superior UK-activating effect and is useful as a pharmaceutical.
    Type: Application
    Filed: November 12, 2013
    Publication date: October 6, 2016
    Applicants: TAISHO PHARMACEUTICAL CO., LTD., NISSAN CHEMICAL INDUSTRIES, LTD.
    Inventors: Shoichi KURODA, Yudai IMAI, Takanori KAWAGUCHI, Keiko FUSEGI, Masahiro BOHNO, Hajime ASANUMA, Tomomichi CHONAN, Nagaaki SATO, Souichi MONMA, Shigetada SASAKO, Marie MIZUTANI, Shin ITOH, Takumi OKADA, Hirofumi OTA, Seishi ISHIYAMA
  • Patent number: 9428483
    Abstract: Provided are a fluorine-containing amino acid prodrug represented by general formula (I) that makes a fluorine-containing amino acid which is a group 2 metabotropic glutamate receptor agonist into a prodrug, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: August 30, 2016
    Assignee: TAISHO PHARMACEUTICAL CO., LTD.
    Inventors: Takashi Hashihayata, Norikazu Otake, Naoki Miyakoshi, Kazunari Sakagami
  • Patent number: 9422240
    Abstract: There are provided compounds having a superior PHD2 inhibitory effect that are represented by general formula (I?): (in the above-mentioned general formula (I?), W, Y, R2, R3, R4, and Y4 are as described hereinabove), or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: July 29, 2013
    Date of Patent: August 23, 2016
    Assignee: TAISHO PHARMACEUTICAL CO., LTD
    Inventors: Tetsuo Takayama, Tsuyoshi Shibata, Fumiyasu Shiozawa, Kenichi Kawabe, Yuki Shimizu, Makoto Hamada, Akira Hiratate, Masato Takahashi, Fumihito Ushiyama, Takahiro Oi, Yoshihisa Shirasaki, Daisuke Matsuda, Chie Koizumi, Sota Kato
  • Publication number: 20160159814
    Abstract: The present invention provides novel compounds of formula [I] or pharmaceutically acceptable salts thereof: which are useful in the prevention or treatment of diseases such as schizophrenia, Alzheimer's disease, cognitive impairment, dementia, anxiety disorders (e.g., generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, acute stress disorder), depression, drug dependence, spasm, tremor, pain, Parkinson's disease, attention deficit hyperactivity disorder, bipolar disorder, eating disorder, or sleep disorders, which is based on the glycine uptake-inhibiting action.
    Type: Application
    Filed: July 25, 2014
    Publication date: June 9, 2016
    Applicant: TAISHO PHARMACEUTICAL CO., LTD.
    Inventors: Daisuki WAKASUGI, Hiroshi OHTA, Kumiko OKADA, Shin-ichi SHIROKAWA, Minoru MORIYA, Tomoko TAMITA, Kumi ABE, Nobutaka HATTORI, Yuko ARAKI